Swedish Orphan Biovitrum (Sobi) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning…
Read More
Novo Nordisk hands a Parkinson’s cell therapy to Cellular Intelligence, a startup trying to design cell behavior
Cellular Intelligence, a rapidly emerging biotech startup formerly known as Somite AI, has secured global rights to a clinical-stage Parkinson’s…
Read More
Gene Therapy Shows Significant Promise in Reversing Fragile X Syndrome Deficits in Mice, Offering Hope for Human Treatment
A groundbreaking study led by the University of California, Riverside (CA, USA) has demonstrated that a novel gene therapy successfully…
Read More
The Future of Cell and Gene Therapy Manufacturing is Being Revolutionized by AI and Advanced Data Strategies
San Diego, CA – The complex landscape of cell and gene therapy manufacturing, a field consistently challenged by the transition…
Read More
Ludwig Cancer Research Study Reveals Novel Combination Therapy to Overcome Differentiation Blockade in Acute Myelogenous Leukemia
The landscape of hematological oncology is facing a potential paradigm shift following the publication of a landmark study by researchers…
Read More
Genprex Secures Canadian Patent for Novel Cancer Therapy Combination
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the…
Read More
UniQure Secures Path to Regulatory Review for Groundbreaking Huntington’s Disease Gene Therapy After FDA Reversal
UniQure has announced a significant turning point in its pursuit of regulatory approval for AMT-130, a pioneering gene therapy aimed…
Read More
Novo Nordisk Transfers Parkinson’s Cell Therapy to Cellular Intelligence, Signaling New Era for AI-Driven Biopharma
In a significant development for the burgeoning field of cell therapy and artificial intelligence in drug discovery, Cellular Intelligence, a…
Read More
SpliSense Advances Promising Cystic Fibrosis Therapy with Significant Funding and Phase IIb Trial Launch
The biotech firm SpliSense is making significant strides in the development of a novel therapy for cystic fibrosis, announcing a…
Read More
AvenCell Therapeutics Unveils Promising Early Data for Switchable Allogeneic CAR-T Therapy in Relapsed/Refractory AML at EHA 2026
AvenCell Therapeutics presented updated results for its CAR-T cell blood cancer therapy at EHA 2026. The European Hematology Association (EHA)…
Read MoreYOU MAY HAVE MISSED
